Balaxi Pharmaceuticals Ltd Q1 Results FY27: Date, Revenue Estimates and What to Expect

Balaxi Pharmaceuticals Ltd is expected to announce its Q1 FY27 (April to June 2026) financial results in July or August 2026. As of July 2026, the stock trades around Rs.24 on NSE with a market capitalisation of approximately Rs.132 Cr and a trailing P/E of 92.0x. This article covers Balaxi Pharmaceuticals Ltd’s Q1 FY27 revenue and PAT estimates, Q4 FY26 actual performance for context, key catalysts and risks, technical levels, and the 12-month share price target.

India’s pharmaceutical sector is seeing sustained domestic formulation growth and recovering export revenues heading into Q1 FY27. The Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 prediction is shaped by these sector Q1 expectations.

This Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 result preview covers Q1 expectations across estimates, catalysts, risks, technicals and the 12-month price target. Specifically, this article covers Balaxi Pharmaceuticals Ltd\’s Q1 FY27 analyst estimates, Q4 FY26 actual performance for context, key catalysts and risks to watch, technical levels, and the 12-month analyst share price target.

Get Free Investment Predictions and Balaxi Pharmaceuticals Ltd Research at Univest

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Ltd (NSE: BALAXI) is a pharmaceutical company listed on the National Stock Exchange and Bombay Stock Exchange. The Balaxi Pharmaceuticals Ltd Q1 Results FY27 is a must-watch Q1 result preview for investors. Q1 FY27 (April to June 2026) results will be a key data point for investors assessing the full-year FY27 earnings trajectory and sector positioning.

Balaxi Pharmaceuticals Ltd reported consolidated Revenue of Rs.71 Cr in Q4 FY26, providing the most recent sequential base against which Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 expectations will be assessed. Q1 FY26 Revenue was Rs.71 Cr, forming the year-on-year comparison base for the Q1 FY27 estimate.

Balaxi Pharmaceuticals Ltd Q1 FY27 Estimates: What to Expect

Balaxi Pharmaceuticals Ltd Q1 FY27 revenue and PAT estimate, results date and 12-month analyst target

Metric	Q1 FY27 Estimate	Q4 FY26 Actual	Context
Revenue	Rs.71-82 Cr	Rs.71 Cr	YoY estimate: +7.8% growth
PAT / Profitability	Near breakeven	Rs.1 Cr	Bottom-line estimate
Results Date	July-August 2026 (TBD)	–	Board meeting for Q1 FY27 approval
12-Month Target	Rs.25-28	–	Tracking

Source: Q4 FY26 actuals from Screener.in; Balaxi Pharmaceuticals Ltd Q1 Results FY27 estimates (Q1 prediction by Uniresearch) are trailing-growth projections. July 2026. Estimates are projections only.

Key Catalysts to Watch in Balaxi Pharmaceuticals Ltd Q1 Results FY27

1. Domestic Formulation Volume Growth

India’s domestic pharma market is growing at 8-10% annually, led by chronic therapies in cardiology, diabetes, and oncology. Companies with strong branded generics portfolios are benefiting from India’s expanding organised healthcare access. Analysts will scrutinise management commentary on this point closely during the Balaxi Pharmaceuticals Ltd Q1 Results FY27 earnings call. This is a core Q1 prediction metric watched by analysts.

2. Export Pipeline and USFDA Filings

A healthy ANDA pipeline and USFDA facility approvals are enabling incremental US generic exports. Recovering API exports to regulated markets are also supporting revenue diversification. Analysts will scrutinise management commentary on this point closely during the Balaxi Pharmaceuticals Ltd Q1 Results FY27 earnings call. This is a core Q1 prediction metric watched by analysts.

3. API Manufacturing Competitiveness

India’s API manufacturing cost advantage is attracting global supply chain partners seeking China-plus-one alternatives, creating a structural demand tailwind for Indian pharma manufacturers. Analysts will scrutinise management commentary on this point closely during the Balaxi Pharmaceuticals Ltd Q1 Results FY27 earnings call. This is a core Q1 prediction metric watched by analysts.

Key Risks for Balaxi Pharmaceuticals Ltd Q1 Results FY27

• USFDA regulatory warnings or Form 483 observations can disrupt US generic export revenues
• US and European generic price erosion can offset new product launch benefits
• Active pharmaceutical ingredient cost inflation can compress formulation margins

Track Balaxi Pharmaceuticals Ltd Q1 Results FY27 Fundamentals on Univest

Monitor Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 expectations and live fundamentals, FII/DII activity, and sector comparison at Univest, a SEBI-Registered Investment Advisor.

Balaxi Pharmaceuticals Ltd Q4 FY26 Performance: Setting the Context

To understand Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 expectations, it is important to contextualise Q4 FY26 (January to March 2026) performance. Balaxi Pharmaceuticals Ltd reported Revenue of Rs.71 Cr and PAT of Rs.1 Cr in Q4 FY26. This performance provides the sequential base against which Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 expectations will be assessed.

The Balaxi Pharmaceuticals Ltd Q1 Results FY27 revenue prediction of Rs.71-82 Cr in Revenue represents +7.8% year-on-year growth versus Q1 FY26 Revenue of Rs.71 Cr. Any material beat or miss relative to these estimates will likely drive meaningful stock price movement on the results day.

Technical Analysis: Balaxi Pharmaceuticals Ltd Share Price Levels

• Current Market Price: Rs.24 on NSE (July 1, 2026) , tracking Balaxi Pharmaceuticals Ltd Q1 Results FY27 ahead of results
• Trailing P/E: 92.0x | Market Cap: Rs.132 Cr
• For the latest 52-week high/low levels, track Balaxi Pharmaceuticals Ltd live on the NSE portal or Univest Screener
• Key resistance: Watch Q1 FY27 results beat/miss relative to the Rs.71-82 Cr revenue estimate as the near-term price catalyst
• The stock’s FY27 trajectory will be shaped by Q1 FY27 results and management guidance on full-year revenue growth

Download the Univest iOS App or Univest Android App to track Balaxi Pharmaceuticals Ltd’s live price, charts, and receive SEBI-backed research alerts.

Balaxi Pharmaceuticals Ltd Share Price Target: Analyst Estimates

Short-Term Target (3 to 6 Months)

In the near term, Balaxi Pharmaceuticals Ltd’s share price will be primarily driven by the Q1 Results FY27 Balaxi Pharmaceuticals Ltd Q1 Results FY27 outcome relative to estimates. A beat on Revenue or PAT, combined with positive management guidance for FY27, could drive the stock toward the higher end of the short-term range of Rs.23 to Rs.27. A miss or cautious guidance would test the lower end of this range.

12-Month Target (Uniresearch Estimate)

The 12-month price target for Balaxi Pharmaceuticals Ltd is estimated at Rs.25 to Rs.28, based on Uniresearch trailing-growth estimates of Rs.71-82 Cr. This implies potential upside from the current market price of Rs.24. Target achievement is contingent on Q1 Results FY27 meeting expectations and FY27 guidance being constructive.

Long-Term View (FY27 to FY28)

Longer-term, the Balaxi Pharmaceuticals Ltd Q1 Results FY27 Q1 result preview will anchor the FY27-FY28 outlook. Longer-term, Balaxi Pharmaceuticals Ltd’s share price trajectory will depend on sector growth trends, market share dynamics, management execution quality, and India’s overall macroeconomic environment. Investors with a 2 to 3 year horizon should evaluate the company on fundamental business quality, ROCE trends, free cash flow generation, and balance sheet health, rather than short-term quarterly movements.

What to Watch on Balaxi Pharmaceuticals Ltd Q1 Results FY27 Day

• Balaxi Pharmaceuticals Ltd Q1 Results FY27 Revenue and PAT numbers relative to Q1 Results FY27 estimates of Rs.71-82 Cr Revenue and Rs.None-None Cr PAT, any material beat or miss will be the primary price driver
• Balaxi Pharmaceuticals Ltd Q1 Results FY27 management guidance: full-year FY27 Revenue and EBITDA margin direction
• Sector-specific operating metrics: domestic formulation volume growth and export pipeline and usfda filings
• Any dividend announcement or capital allocation guidance
• Management commentary on macro headwinds including commodity costs, rupee movement, and demand outlook

Conclusion

Balaxi Pharmaceuticals Ltd’s Q1 Results FY27 are one of the key earnings events for India’s pharmaceutical sector in the July to August 2026 results season. With the stock trading at Rs.24 and analyst targets pointing to Rs.25 to Rs.28 over 12 months per Uniresearch trailing-growth estimates, the Q1 FY27 outcome will be a critical catalyst for determining whether the stock achieves or delays its implied upside. Monitor the Univest research platform for Balaxi Pharmaceuticals Ltd Q1 Results FY27 real-time commentary, Q1 predictions and Q1 expectations post the Q1 result preview, post-result analysis, and updated price targets after results are declared.

Frequently Asked Questions on Balaxi Pharmaceuticals Ltd Q1 Results FY27

When is Balaxi Pharmaceuticals Ltd Q1 Results FY27 date?

Ans. The Balaxi Pharmaceuticals Ltd Q1 Results FY27 date has not been officially announced yet. Q1 FY27 (April to June 2026) results for NSE-listed companies are typically declared in July or August 2026. The board meeting notice will be published on the NSE and BSE filing portals. Check the NSE or BSE filing portal for the exact Balaxi Pharmaceuticals Ltd Q1 Results FY27 date once it is announced.

What is the Balaxi Pharmaceuticals Ltd Q1 FY27 revenue estimate?

Ans. The Balaxi Pharmaceuticals Ltd Q1 FY27 revenue estimate based on Uniresearch trailing-growth analysis is Rs.71 to Rs.82 Cr, representing +7.8% year-on-year growth against Q1 FY26 Revenue of Rs.71 Cr. Actual Q1 FY27 revenue may differ from this estimate.

What is the Balaxi Pharmaceuticals Ltd share price target?

Ans. The 12-month price target for Balaxi Pharmaceuticals Ltd is estimated at Rs.25 to Rs.28 based on Uniresearch trailing-growth estimates and current valuation. The stock trades at Rs.24 with a trailing P/E of 92.0x as of July 2026. Targets are subject to revision based on Q1 Results FY27 and FY27 guidance.

Is Balaxi Pharmaceuticals Ltd a good buy before Q1 FY27 results?

Ans. Investing ahead of quarterly results carries earnings risk. Stocks can fall sharply on results misses regardless of prior technical setup. The appropriate approach is to assess whether Balaxi Pharmaceuticals Ltd offers a good risk-reward at current levels of Rs.24 relative to both the bull case (beat plus positive guidance) and the bear case (miss plus cautious commentary). Consult a SEBI-registered financial advisor before making any investment decision.

What should I watch for in Balaxi Pharmaceuticals Ltd Q1 Results FY27?

Ans. Key metrics to monitor for Balaxi Pharmaceuticals Ltd Q1 Results FY27: Revenue performance versus the estimate of Rs.71 to Rs.82 Cr; PAT versus estimate; management guidance for FY27; domestic formulation volume growth progress; and management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export revenues.

Where can I find Balaxi Pharmaceuticals Ltd Q1 Results FY27?

Ans. Balaxi Pharmaceuticals Ltd’s Q1 Results FY27 will be available on the BSE (bseindia.com) and NSE (nseindia.com) filing portals immediately after the board meeting. For real-time analysis, expert commentary, and updated price targets after results are declared, download the Univest app or visit the Univest website.